TY - JOUR
T1 - Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
AU - Boeve, Bradley F.
N1 - Funding Information:
I have served as an investigator for clinical trials sponsored by Cephalon, Allon Pharmaceuticals, and GE Healthcare. I receive royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009) and have received honoraria from the American Academy of Neurology. I serve on the Scientific Advisory Board of the Tau Consortium and receive research support from the National Institute on Aging ( P50 AG016574, U01 AG006786, RO1 AG032306, RO1 AG041797 ) and the Harry T Mangurian Foundation.
Funding Information:
I am supported by grants AG015866, AG016574, AG006786, NS040256 , the Harry T Mangurian Jr Foundation for Lewy body dementia research, and the Robert H and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation .
PY - 2013/5
Y1 - 2013/5
N2 - Parkinson's disease is a progressive neurodegenerative disorder associated with Lewy body disease pathology in central and peripheral nervous system structures. Although the cause of Parkinson's disease is not fully understood, clinicopathological analyses have led to the development of a staging system for Lewy body disease-associated pathological changes. This system posits a predictable topography of progression of Lewy body disease in the CNS, beginning in olfactory structures and the medulla, then progressing rostrally from the medulla to the pons, then to midbrain and substantia nigra, limbic structures, and neocortical structures. If this topography and temporal evolution of Lewy body disease does occur, other manifestations of the disease as a result of degeneration of olfactory and pontomedullary structures could theoretically begin many years before the development of prominent nigral degeneration and the associated parkinsonian features of Parkinson's disease. One such manifestation of prodromal Parkinson's disease is rapid eye movement (REM) sleep behaviour disorder, which is a parasomnia manifested by vivid dreams associated with dream enactment behaviour during REM sleep. Findings from animal and human studies have suggested that lesions or dysfunction in REM sleep and motor control circuitry in the pontomedullary structures cause REM sleep behaviour disorder phenomenology, and degeneration of these structures might explain the presence of REM sleep behaviour disorder years or decades before the onset of parkinsonism in people who develop Parkinson's disease.
AB - Parkinson's disease is a progressive neurodegenerative disorder associated with Lewy body disease pathology in central and peripheral nervous system structures. Although the cause of Parkinson's disease is not fully understood, clinicopathological analyses have led to the development of a staging system for Lewy body disease-associated pathological changes. This system posits a predictable topography of progression of Lewy body disease in the CNS, beginning in olfactory structures and the medulla, then progressing rostrally from the medulla to the pons, then to midbrain and substantia nigra, limbic structures, and neocortical structures. If this topography and temporal evolution of Lewy body disease does occur, other manifestations of the disease as a result of degeneration of olfactory and pontomedullary structures could theoretically begin many years before the development of prominent nigral degeneration and the associated parkinsonian features of Parkinson's disease. One such manifestation of prodromal Parkinson's disease is rapid eye movement (REM) sleep behaviour disorder, which is a parasomnia manifested by vivid dreams associated with dream enactment behaviour during REM sleep. Findings from animal and human studies have suggested that lesions or dysfunction in REM sleep and motor control circuitry in the pontomedullary structures cause REM sleep behaviour disorder phenomenology, and degeneration of these structures might explain the presence of REM sleep behaviour disorder years or decades before the onset of parkinsonism in people who develop Parkinson's disease.
UR - http://www.scopus.com/inward/record.url?scp=84876491370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876491370&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(13)70054-1
DO - 10.1016/S1474-4422(13)70054-1
M3 - Review article
C2 - 23578773
AN - SCOPUS:84876491370
SN - 1474-4422
VL - 12
SP - 469
EP - 482
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 5
ER -